The Clinical Neuro-Oncology Program at Emory's Winship Cancer Institute serves as a one stop treatment for patients with brain and spinal cord tumors and functions as a multidisciplinary brain/spinal cord tumor clinic and real time tumor board.
With a team of professionals from the fields of neuropathology, neuroradiology, nuerosurgery, and neuro-oncology and laboratory scientists of the Winship Brain Tumor Program for rapid translational research, and neurosurgery, the Neuro-Oncology team at Winship offers patients faster, more effective treatment.
Directed by Alfredo Voloschin, MD, the Clinical Neuro-Oncology Program holds a weekly Brain Tumor Conference to discuss management of cases from a multidisciplinary team of Neuro-Oncology, Neuro-radiology, Radiation Oncology, Pathology, and Neurosurgery. Jeffrey Olson, MD and Costas Hadjipanayis, MD, PhD are also part of the team.
The Neuro-Oncology Program is a member of the "New Approaches to Brain Tumor Therapy" (NABTT) CNS Consortium. The goal of the program is to improve the therapeutic outcome for adults with primary brain tumors.
This consortium is one of two programs nationwide that is funded by the National Cancer Institute to conduct Phase I and Phase II clinical evaluations of promising new treatment strategies, routes of administrations, and clinical trial design in the treatment of primary malignancies of the central nervous system. The primary goals of the NABTT CNS Consortium are to develop scientific advances and improve clinical outcomes for patients with primary brain tumors.
Winship currently offers treatment trials for newly diagnosed and malignant brain tumors sponsored by NABTT, as well as ones from industrial sources and originated at Emory.